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Glioblastoma is the most common primary brain tumor in the adult and carries a poor prog-
nosis with a median survival of only 14 months. Patients with glioblastoma are followed
with MRI scans, but this technique has several limitations including low specificity to dif-
ferentiate between tumor and treatment effect. Development of serum markers could
significantly improve the care of glioblastoma patients. We review the current concept
of developing YKL-40 as one of the most promising serum markers for glioblastoma, the
recent advances on understanding the role of YKL-40 in gliomagenesis, and the promising
evidence emerging from preclinical models on using this protein as a target for anti-glioma
therapy.
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INTRODUCTION
Glioblastoma is the most common primary brain tumor in
the adult and despite aggressive tumor resection and chemora-
diation, the median survival of glioblastoma patients is only
about 14 months (1). Although pathologically characterized by
high tumor cell proliferation, necrosis, and neovascularization,
glioblastomas are molecularly heterogeneous and highly dynamic
tumors throughout the course of the disease. Patients with
glioblastoma are followed clinically with MRI scans but this tech-
nique has several limitations including the inability to reliably
distinguish between tumor progression and effects of treatment.
Multiple brain tumor samplings during the disease course are
also not feasible and less invasive tests such as serum markers
could significantly improve glioblastoma patient care. YKL-40, a
chitinase homolog also called human cartilage glycoprotein 39 or
chitinase 3-like 1, is one the most promising serum markers for
glioblastoma currently in development. YKL-40 is overexpressed
in glioblastoma, secreted into the bloodstream, and easily and reli-
ably measured in serum. Moreover, YKL-40 is involved in glioblas-
toma pathophysiology and may be a promising anti-glioblastoma
therapeutic target.
YKL-40 IS A GLYCOPROTEIN OVEREXPRESSED IN
GLIOBLASTOMA
CHI3L1/YKL-40 is one of the most differentially overexpressed
genes in glioblastoma relatively to normal brain and low grade
gliomas, as revealed by Tanwar et al. (2). There was no difference
in expression between low-grade gliomas and normal brain (2).
The overexpression of YKL-40 mRNA in glioblastoma relatively
to undetectable expression in low-grade gliomas and normal
brain was confirmed by using Western Blot to measure the rel-
ative amounts of the YKL-40 protein. Furthermore, the YKL-40
glycoprotein could be detected in the serum of patients with
glioblastoma and other high-grade gliomas (2–4). In children,
however, YKL-40 is less often detected in glioblastoma suggesting
that the underlying biology of glioblastoma in childhood might
differ from the adult (5). Immunohistochemistry analysis detects
YKL-40 expression mainly in the cytoplasm of tumor cells and
reactive astrocytes, but the expression is low in macrophages and
neurons mixed within the tumor (6, 7). The extracellular release
of the protein into circulation suggests that the protein is a ligand,
making it a potential target for neutralizing antibodies. Neverthe-
less, the receptors that YKL-40 might bind to initiate signaling
transduction remain elusive, with the exception of endothelial
cells, where YKL-40 is proposed to bind a membrane receptor
syndecan-1 and integrin αvβ3 (8).
MOLECULAR CHARACTERISTICS OF BRAIN TUMORS
EXPRESSING YKL-40
The expression of YKL-40 in tumor xenografts obtained from the
intracranial injection of cells dissociated from glioblastoma previ-
ously treated with chemotherapy or radiotherapy, and sorted for
the stem cell marker CD133 was only detected in the CD133+
tumors (9). These CD133+ tumors had pathological characteris-
tics consistent with glioblastoma with pseudopalisading necrosis
and microvascular proliferation and stained for the endothelial cell
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marker CD31/PECAM-1 (9). In another report by Liu et al. that
utilized the culture of glioblastoma dissociated cells under stem
cell conditions with subsequent differentiation in the presence of
serum, EDN3 mRNA, known to be involved in the development
of neural crest-derived cells lineages, and CD133 mRNA were
decreased under differentiation conditions while EDN1 and YKL-
40 mRNA were upregulated (10). In this particular study, tumor
xenografts generated by implantation of cells sorted according to
CD133 expression, showed that YKL-40 mRNA was found only
on the tumors generated by the CD133− cells. The discrepancy
between the results of both works concerning the CD133 cell frac-
tion expressing YKL-40 may be related to cell-lineage expression
pattern of CD133 and to a different cell of origin for glioblastoma
among the various glioblastoma subclasses, as we have previously
pointed out (11). We and others have also found CD133 to be
expressed in high grade glioma vasculature (10, 12). Additionally,
we identified specific genes upregulated in CD133+ endothe-
lium that code for signaling factors, such as endothelin, lipocalin,
selectin, and PDGF that by themselves may be implicated on
glioma angiogenesis, proliferation, and survival (10) (Figure 1).
YKL-40 expression was identified by the Cancer Genome Atlas
to be a marker for the mesenchymal subtype of glioblastoma (13).
The upregulation of YKL-40 characterizes primary glioblastoma
and was not found in secondary glioblastoma, which showed a
downregulation of the CHI3L1 gene (14). In vitro studies showed
that YKL-40 was associated with chromosome 10 loss, increased
FIGURE 1 | Model depicting the interaction of tumor cells within the
microenvironment, predominantly with endothelial cells. While EGFR
has been thoroughly and the most well studied and yet, not successful
target signaling cascade in gliomas, YKL-40 may also promote glioma
proliferation and survival, by inducing angiogenesis, through VEGF
upregulation (thick arrow) and by VEGF-independent pathways (thin arrow),
after persistent blockade of VEGF. Hypothetical, in a VEGF independent
mechanism, YKL-40 secreted by the glioma cell modulates upon activation
of CD133+ endothelial cells, the expression of endothelial-derived factors
that are capable of triggering tumor angiogenesis and feedback to glioma
cells, some of which also express the stem cell marker CD133+, promoting
tumor growth.
resistance to radiotherapy, capacity of invasion, and metallopro-
teinase activity (15, 16). In anaplastic oligodendroglioma, loss
of heterozygosity in chromosome 10q correlated with increased
YKL-40 expression but no correlation was found with 1p19q
codeletion. YKL-40 expression was lower in tumors with EGFR
amplification or EGFR immunostaining (7). Survival of patients
who have a glioblastoma that does not express either YKL-40 or the
EGFR variant, EGFRvIII, was longer and the disease had a better
outcome (17).
DETECTION OF CIRCULATING YKL-40 PROTEIN IN PATIENTS
WITH GLIOBLASTOMA
Circulating YKL-40, which is secreted by glioblastoma cells can be
easily measured in serum through ELISA. There is no significant
circadian variation in YKL-40 serum levels (18) and the protein
levels are stable in collected blood for up to 7 days. A prospective
longitudinal study correlated serum levels of YKL-40 with MRI
findings in 197 patients with glioblastoma (4). Serum YKL-40
levels were significant lower in glioblastoma patients with no radi-
ographic evidence of disease compared to those with radiographic
evidence of tumor. Moreover, a doubling or higher increases of
the serum YKL-40 level was seen in 47% of glioblastoma patients
over time. Importantly, this increase in YKL-40 levels was inde-
pendently associated with a shorter survival, and it was the most
predictive prognostic marker when compared to age, extent of
tumor resection or performance status (4).
A smaller study of 60 patients with glioblastoma who under-
went gross total or subtotal resection showed that levels dropped
postoperatively more often in patients who had more exten-
sive tumor resections (19). Additionally, patients who had post-
operatively an increase in YKL-40 serum levels by 100% or higher,
had a very short median survival of only 76 days (19).
YKL-40 EXPRESSION IN GLIOBLASTOMA TUMOR TISSUE
AND PROGNOSIS
Pelloski et al. reported on 140 glioblastoma patients who under-
went gross-total resection and immunohistochemistry was per-
formed on tumor tissue for YKL-40 expression (16). Eighty (57%)
tumors were strongly stained (score 2+) for YKL-40, 37 (26%) had
an intermediate level of staining (score 1+), and 23 (16%) were
negative (score 0). Patients with YKL-40 scores of 0 in this group
had a median overall survival of 116 weeks, compared to a median
survival of 53 weeks for patients whose tumors had 1+ staining,
and 41 weeks for those with scores of 2+.
Another independent study by Colman et al. using four datasets
of mRNA expression in glioblastomas identified a 9-gene set,
which included YKL-40, as the most predictive for prognosis
among more than 10,000 genes evaluated by mRNA microar-
rays (20). This nine-gene set that included YKL-40 was then
validated looking at protein expression by immunohistochem-
istry on formalin-fixed glioblastoma tissue, which is more widely
available compared to frozen tumor tissue required for mRNA
expression (20).
Another study of 105 patients with glioblastoma showed that
extent of resection, MGMT promoter methylation status and YKL-
40 expression by immunohistochemistry were the most important
prognostic factors in newly diagnosed glioblastomas (21).
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REGULATION AND FUNCTION OF YKL-40 IN GLIOMA
In recent years, advances have been made that shed light on the
role of YKL-40 in glioma biology. Human embryonic kidney 293
cells transfected with CHI3L1/YKL-40 became transformed and
initiated tumors when transplanted into the rat brain (22). Sta-
ble transfection of astrocytes with CHI3L1 conferred resistance
to radiation and increased invasion capacity (15). In a chick
chorioallantoic membrane assay, the inhibition of VEGFA by RNA
interference in human glioma cells produced avascular tumors
that revealed an upregulation of CHI3L1/YKL-40 (23). Expo-
sure of U87 cells to stress, including hypoxia, ionizing radiation,
and chemotherapy with etoposide or serum depletion, resulted in
increased YKL-40 levels in the culture media, suggesting that YKL-
40 promoted survival of cancer cells in adverse conditions (24).
Supporting these findings, the knockdown of CHI3L1/YKL-40
reduced glioma invasion, increased cell death induced by cisplatin,
etoposide, and doxorubicin, and decreased cell–matrix adhesion
and expression of MMP-2 (25).
There is supporting evidence for the role of YKL-40 in glioma
cell proliferation by activation of MAPK and AKT pathways (6). In
fact, inhibition of YKL-40 expression by siRNA, led to cell arrest in
G1 and decreased activity of phospho-ERK1/2 and phospho-AKT
(6). NF-κB pathway is also associated with CHI3L1/YKL-40. TNF-
α recruits p65 and p50 subunits of NF-κB to the CHI3L1/YKL-40
promoter, suppressing the expression of YKL-40 in glioma cell
lines. TNF-α recruits histone deacetylases, HDAC1 and HDAC2,
promoting deacetylation of histone H3 at the CHI3L1/YKL-40
promoter in a cell type specific manner (26). REL B, a protein
belonging to the NF-κB protein complex promotes expression
of genes belonging to the mesenchymal glioblastoma subtype,
including CHI3L1/YKL-40 (27). Loss of REL B led to lower levels
of YKL-40 protein and decreased tumor size, and when overex-
pressed, it upregulated CHI3L1/YKL-40 mRNA (27). In contrast,
TNF-α promotes mesenchymal transformation of a proneural
glioma stem cell line and increase in YKL-40 and CD44 expres-
sion through activation of NF-κB. In addition, transformation
from proneural to mesenchymal glioma stem cell line, increased
radioresistance in an NF-κB dependent manner (28).
Overexpression of a splice variant of a transcription repressor
NF-X, designated NFI-X3 (nuclear factor I-X3) enhanced YKL-
40 expression in glioma cells by binding the regulatory elements
of CHI3L1/YKL-40 promoter, activating transcription, promoting
invasion, and migration (29). Variant alleles of CHI3L1/YKL-40
promoter GG, CC, and GC in tumors had no significant impact
on the survival of patients, notwithstanding those that have GG
variant tended to have longer survival (30).
STRATEGIES TO TARGET YKL-40 IN GLIOBLASTOMA
The first steps for therapy to target YKL-40 are on the way as
the regulation and function of YKL-40 gets unveiled. Among
possible approaches is modulation of NF-κB signaling and inhi-
bition of ERK1/2 pathway. Resveratrol, a plant phenol inhibited,
in vitro, the proliferation and invasion of U87 cells by decreas-
ing the activity of CHI3L1/YKL-40 promoter and lowering the
levels of mRNA transcript and YKL-40 protein expression (31).
Floyd et al. (32) found that YKL-40 may be involved in the Notch
pathway by inhibiting cleavage of Notch1 by treating cells with
a α-secretase inhibitor, INCB3619. The authors also showed that
there was an increase in survival and decrease in tumor size of
their xenograft tumor model when treated with the α-secretase
inhibitor, by using nanoparticles as the drug delivery system (32).
They saw no effect when a γ-secretase inhibitor was used instead.
Okada et al. (33) conducted a phase I/II trial to evaluate the safety
and immunogenicity of a vaccine using polarized dendritic cells
loaded with polyinosinic–polycytidylic acid stabilized by lysine
and carboxymethylcellulose (poly-ICLC) and synthetic peptides
for glioma-associated antigens including YKL-40. The vaccine was
well tolerated, immunogenicity was developed, and preliminary
clinical activity was seen.
More recently, it has been shown that YKL-40 is associ-
ated with tumor angiogenesis. This is particularly interesting in
glioblastoma, which is one most vascularized human cancers,
and vascular proliferation is one of its pathological hallmarks.
Francescone et al. (34) showed that YKL-40 upregulated vascu-
lar endothelial growth factor (VEGF), which is considered the
primary promoter of angiogenesis in glioblastoma. More specif-
ically, YKL-40 was found to induce interaction of the membrane
receptors syndecan-1 and integrin αvβ5, and triggered a signal-
ing cascade through FAK to ERK-1 and ERK-2, leading to ele-
vated VEGF expression and enhanced angiogenesis (34). Both
VEGF and YKL-40 had synergistic effects on tumor angiogene-
sis, however persistent blockage of VEGF led to upregulation of
YKL-40, supporting that glioblastoma eventually develop VEGF-
independent pathways of tumor vascularization (Figure 1); this
may be one of the mechanisms that explains why glioblastoma
always becomes resistant to anti-VEGF treatment such as beva-
cizumab. Faibish et al. (35) developed a YKL-40 monoclonal
neutralizing antibody, mAY that blocked, in a dose dependent
manner, tube formation induced by U87 conditioned medium
expressing YKL-40. Tumors obtained in xenografts by subcuta-
neous implantation of U87 cells into SCID/Beige mice that were
subsequently treated with mAY antibody, had smaller volume and
exhibited decreased angiogenesis. Moreover, preclinical studies
suggest (36).
In conclusion, glioblastoma is a heterogeneous tumor with
multiple pathways that have a different relevance and implication
in tumorigenesis among tumors with the same histological pat-
tern. YKL-40 as a serum marker possibly reflects the biology not
only of tumor cells but also of the microenvironment (Figure 1).
Endothelial cells in the tumor microenvironment, likely, may have
various levels of heterogeneity among the glioblastoma tumors.
Angiogenesis therapeutic is complex, and future trials may need to
combine anti-VEGF treatment with anti-YKL-40 target therapy to
control glioma cell growth with inactivation of angiogenic factors.
In addition, YKL-40 is involved in the pathogenesis of the mes-
enchymal glioblastomas, which are the most aggressive molecular
subtype of these tumors. Further studies are needed to evaluate
if longitudinal serum YKL-40 measurements could be a reli-
able marker for diagnosis of glioma transformation from the less
aggressive proneural subtype to the more aggressive mesenchymal
subtype.
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